The latter is an FDA approved kinase inhibitor for the treatment of adult patients with newly diagnosed, FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia in combination with standard cytarabine and daunorubicin induction, and cytarabine consolidation, or with aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm or mast cell leukemia. The gene discussed is FLT3; the disease is systemic mastocytosis.